REMAP-CAP to study IFN beta-1a effect in COVID-19
Faron Pharmaceuticals Oy ("Faron" or the "Company") Global Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) to study the effect of interferon beta-1a in COVID-19 Company announcement, 1 April 2020 at 9.00 AM (EEST)Inside information TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that regulatory approval has been granted for the global Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-